Morgan Stanley Inmune Bio, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 27,479 shares of INMB stock, worth $221,755. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,479

Previous 12,803 114.63%

Holding current value

$221,755

Previous $144,000 123.61%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.53 - $14.01 $154,538 - $205,610	14,676 Added 114.63%	27,479 $322,000
Q4 2023 Feb 13, 2024	BUY	$6.6 - $11.52 $57,565 - $100,477	8,722 Added 213.72%	12,803 $144,000
Q3 2023 Nov 15, 2023	SELL	$6.61 - $10.9 $6,034 - $9,951	-913 Reduced 18.28%	4,081 $27,000
Q2 2023 Aug 14, 2023	BUY	$6.5 - $10.09 $1,150 - $1,785	177 Added 3.67%	4,994 $45,000
Q1 2023 May 15, 2023	BUY	$6.01 - $10.18 $10,992 - $18,619	1,829 Added 61.21%	4,817 $31,000

Q4 2022 Feb 14, 2023	SELL	$6.31 - $7.96 $795,135 - $1 Million	-126,012 Reduced 97.68%	2,988 $18,000
Q3 2022 Nov 14, 2022	SELL	$6.91 - $10.44 $547,838 - $827,704	-79,282 Reduced 38.06%	129,000 $800,000
Q2 2022 Oct 27, 2022	SELL	$5.48 - $8.97 $505,250 - $827,025	-92,199 Reduced 30.68%	208,282 $1.84 Million
Q2 2022 Aug 15, 2022	SELL	$5.48 - $8.97 $505,250 - $827,025	-92,199 Reduced 30.68%	208,282 $1.84 Million
Q1 2022 Oct 27, 2022	BUY	$6.42 - $11.39 $591,917 - $1.05 Million	92,199 Added 44.27%	300,481 $2.53 Million
Q1 2022 May 13, 2022	SELL	$6.42 - $11.39 $500,798 - $888,488	-78,006 Reduced 20.61%	300,481 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$9.97 - $20.38 $3.53 Million - $7.21 Million	353,856 Added 1436.63%	378,487 $3.86 Million
Q3 2021 Nov 15, 2021	BUY	$14.13 - $27.85 $348,036 - $685,973	24,631 New	24,631 $478,000

Others Institutions Holding INMB

# of Institutions

Shares Held

2.88M

Call Options Held

44.6K

Put Options Held

3.5K

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $145M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account